Beers List and Cough Suppressants in Elderly Patients
For elderly patients requiring cough suppression, dextromethorphan is the preferred agent at therapeutic doses of 60 mg, while avoiding first-generation antihistamines like promethazine due to their inclusion on the Beers Criteria for potentially inappropriate medications in older adults. 1, 2
Recommended Cough Suppressants for Elderly Patients
First-Line Agent: Dextromethorphan
- Dextromethorphan is the preferred central cough suppressant with a superior safety profile compared to opioid alternatives like codeine, making it particularly suitable for elderly patients. 1, 2
- Standard over-the-counter dosing (15-30 mg) is subtherapeutic; maximum cough reflex suppression occurs at 60 mg doses and provides prolonged relief. 1, 3, 2
- Dextromethorphan is recommended for short-term symptomatic relief in patients with chronic bronchitis (duration typically less than 7 days). 4, 1
- Use caution with combination preparations containing paracetamol or other ingredients that may require dose adjustment in elderly patients. 3
Alternative First-Line Option: Ipratropium Bromide
- Ipratropium bromide is the only recommended inhaled anticholinergic agent for cough suppression and is particularly effective in elderly patients with chronic bronchitis or COPD. 4
- In stable patients with chronic bronchitis, ipratropium bromide reduces cough frequency, severity, and sputum volume. 4
- This agent has substantial benefit with Grade A recommendation for cough suppression. 4
Peripheral Cough Suppressants
- Levodropropizine and moguisteine are recommended for short-term symptomatic relief in patients with chronic or acute bronchitis, with substantial benefit (Grade A). 4
- These peripheral agents show the highest level of benefit and are particularly suitable when central suppressants are contraindicated. 5
Medications to AVOID in Elderly Patients
Beers Criteria Concerns
- First-generation antihistamines (including promethazine, diphenhydramine) should be avoided in elderly patients despite their cough suppressant properties due to significant anticholinergic effects, sedation, and fall risk. 1, 2
- While these agents can suppress nocturnal cough, their sedative properties pose substantial risks in the elderly population. 1, 3
Opioid-Based Suppressants
- Codeine and pholcodine should NOT be prescribed as they have no greater efficacy than dextromethorphan but carry a much greater adverse side effect profile including drowsiness, nausea, constipation, and physical dependence. 3, 2
- Theophylline should be avoided in elderly patients due to concerns over side effects and drug interactions, despite some efficacy for chronic cough. 4
Clinical Algorithm for Elderly Patients with Cough
Step 1: Assess Cough Characteristics
- Determine if cough is productive or non-productive (dry cough requires suppression; productive cough may need clearance facilitation). 1, 2
- Evaluate duration: acute (<3 weeks), subacute (3-8 weeks), or chronic (>8 weeks). 2
- Screen for underlying COPD, chronic bronchitis, or other respiratory conditions. 4
Step 2: Initial Management
- For non-productive cough: Start with dextromethorphan 60 mg for maximum suppression. 1, 2
- For patients with COPD/chronic bronchitis: Consider ipratropium bromide as first-line to address both bronchodilation and cough suppression. 4
- Consider simple home remedies (honey and lemon) as initial approach for benign viral cough before pharmacological treatment. 1, 3, 2
Step 3: Duration and Reassessment
- Limit antitussive therapy to short-term use (typically less than 7 days). 1
- If cough persists beyond 3 weeks, mandatory reassessment is required to rule out other causes rather than continuing antitussive therapy. 2
- Beyond 21 days, cough is no longer acute and requires full diagnostic workup. 2
Critical Pitfalls to Avoid
- Do not use subtherapeutic doses of dextromethorphan (<60 mg); standard OTC dosing is often inadequate. 1, 3, 2
- Avoid prescribing first-generation antihistamines to elderly patients even for nocturnal cough due to Beers Criteria concerns. 1, 2
- Do not suppress productive cough in conditions like pneumonia or bronchiectasis where secretion clearance is essential. 2
- Do not continue antitussive therapy beyond 2-3 weeks without investigating underlying causes. 2
- Review all medications to exclude ACE inhibitor-induced cough, which occurs in up to 16% of patients and resolves only with drug cessation. 3
Special Considerations for COPD Patients
- In patients with COPD, treat the underlying disease first rather than suppressing cough if it serves a protective clearance function. 2
- Short-acting β-agonists or anticholinergic bronchodilators should be administered during acute exacerbations. 4
- Manually assisted cough may be detrimental in COPD patients and should not be used. 4